MQT DDVis - An installation-free web-tool which visualizes quantum decision diagrams and allows to explore their behavior when used in design tasks such as simulation, synthesis, or verification.

Re­gen­eron can’t dodge a law­suit al­leg­ing it un­law­ful­ly in­flat­ed Medicare re­im­burse­ments for its eye drug Eylea and de­fraud­ed the US out of hun­dreds of mil­lions … ...

The US government can continue to allege that Regeneron Pharmaceuticals Inc. violated the False Claims Act by overcharging Medicare for its drug Eylea, which is used to treat age-related vision ...

Lead drug Eylea had global sales of just under $10 billion in 2024 and is approved for wet age-related macular degeneration and other eye-related indications. The majority of sales are for ...

In the first quarter, U.S. net sales for Eylea HD and Eylea decreased 26% year-over-year to $1.04 billion, including $307 million from Eylea HD. Also Read: FDA Sets The Countdown: Regeneron’s ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Total revenues decreased 4% year over year to $3 billion due to lower sales of lead drug Eylea. Revenues also missed the Zacks Consensus Estimate of $3.27 billion. Sales of oncology drug ...

Eylea sales fell 26% to $1.04 billion amid pricing pressure and market share loss; Eylea HD saw increased volume. Don’t miss this list of 10 overlooked stocks—including one paying a 9% ...

U.S. sales of Eylea, jointly developed with Bayer, fell 26% in the first quarter to $1.04 billion. First-quarter revenue was $3.03 billion, below expectations of $3.27 billion.

Accused of “warming the market” for a new Eylea indication, the German drugmaker successfully argued on appeal that an advisory board was in fact legitimate. An anonymous complainant sparked ...

Meanwhile, its high-dose version, known as Eylea HD, brought in $453M, with over a twofold rise from the prior year period. Meanwhile, REGN’s asthma drug Dupixent, marketed with Sanofi (SNY ...